Cancer Treatment Alternatives Beyond HBOT Explored
In this segment, the speaker compares photodynamic therapy (PDT), especially using red‑light wavelengths, to hyperbaric oxygen therapy (HBOT) as adjuncts in cancer treatment. Historically, both modalities were approached with caution due to concerns they might promote tumor growth. The speaker notes that since roughly 2012‑2015, clinical experience and research have shifted the narrative, showing PDT can be beneficial rather than harmful. However, manufacturers often retain cancer‑risk warnings, and regulatory stances differ worldwide: European and Asian practitioners have largely relaxed these cautions, while many North American clinicians remain skeptical. The overall tone conveys a cautiously optimistic view that the red‑spectrum PDT may aid cancer patients, but acknowledges lingering regulatory and perceptual barriers.
